Group 1 - The company reported its H1 2025 results, with revenue of 2.788 billion yuan, a decrease of 4.3% year-on-year, and a net profit attributable to shareholders of 274 million yuan, an increase of 64.1% year-on-year [1] - In Q2 2025, revenue was 1.389 billion yuan, a slight decrease of 0.5% year-on-year, while net profit attributable to shareholders surged by 134% to 179 million yuan [1] - The gross margin for H1 2025 remained stable at 59.67%, while the net profit margin decreased to 10.6%, down 4.4 percentage points year-on-year [1] Group 2 - The medical beauty segment generated revenue of 1.333 billion yuan in H1 2025, a decline of 6.1%, accounting for 47.8% of total revenue, with a gross margin of 54.54% [2] - The fashion women's wear business reported revenue of 988 million yuan, a decrease of 2.42%, with a gross margin of 65.15%, and online sales accounted for 46.3% of total revenue [2] - The green baby and child segment generated revenue of 435 million yuan, a decline of 3.43%, with a gross margin of 62.4% [2] Group 3 - The company is driven by three main segments: fashion women's wear, green baby and child, and medical beauty, with plans for continuous expansion through self-built and acquisition strategies [3] - The competitive landscape in the medical beauty sector is fragmented, with expectations for consolidation towards leading players, supported by the company's 1+N strategy [3] - The company has adjusted its profit forecast for 2025 to 370 million yuan, up from the previous estimate of 270 million yuan, with projected net profits for 2026 and 2027 at 290 million yuan and 310 million yuan, respectively [3]